[Multiple sclerosis management system 3D. Moving from documentation towards management of patients].
BACKGROUND
The increasing therapeutic options for relapsing-remitting multiple sclerosis require a specific treatment and risk management to recognize the individual response as well as potential side effects. To switch from pure MS documentation to MS management by implementing a new multiple sclerosis management and documentation tool may be of importance.


METHODS
This article presents the novel computer-based patient management system "multiple sclerosis management system 3D" (MSDS 3D).


RESULTS
MSDS 3D allows documentation and visualization of visit schedules and mandatory examinations via defined study modules by integration of data input from patients, attending physicians and MS nurses. It provides forms for the documentation of patient visits as well as clinical and diagnostic findings. Information is collected via interactive touch screens. A specific module which is part of MSDS 3D's current version allows the monthly monitoring of patients under treatment with natalizumab. A checklist covering clinical signs of progressive multifocal leukoencephalopathy (PML) and a detailed questionnaire about the handling of natalizumab in practice have additionally been added.


CONCLUSIONS
The MS patient management system MSDS 3D has successfully been implemented and is currently being evaluated in a multi-centre setting. Advanced assessment of patient data may allow improvements in clinical practice and research work. The addition of a checklist and a questionnaire into the natalizumab module may support the recognition of PML during its early, treatable course.
Klinik für Neurologie, Universitätsklinik Dresden, Fetscherstr. 74, 01307, Dresden, Deutchland. thorsten.schultheiss@uniklinikum-dresden.de
T
T
Schultheiss
R
R
Kempcke
F
F
Kratzsch
M
M
Eulitz
M
M
Pette
H
H
Reichmann
T
T
Ziemssen
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D020000:Decision Support Systems, Clinical / Q000458:organization & administration*; D003936:Diagnosis, Computer-Assisted / Q000379:methods; D004282:Documentation / Q000379:methods*; D006801:Humans; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000188:drug therapy*; D000069442:Natalizumab; D012984:Software; D017216:Telemedicine / Q000379:methods*; D013813:Therapy, Computer-Assisted / Q000379:methods*; D014584:User-Computer Interface
D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab